The 18th Annual Non-Dilutive Funding Summit

The 18th Non-Dilutive Funding Summit brought together hundreds of life science industry leaders with directors at ARPA-H, BARDA, SEED, NIA, NHLBI, NIAID, NINDS, and CIRM, so the innovators could learn about non-dilutive funding opportunities for their R&D directly from the funding agencies.

This free summit is hosted by the FreeMind Group. FreeMind helps companies secure non-dilutive funding for life science R&D and wins over $100 million each year for clients. Follow us on LinkedIn or get our newsletter for news about non-dilutive funding opportunities, announcements about conferences with the best partnering, and discounts for those conferences. The 19th Non-Dilutive Funding Summit will be January 10, 2024.

Advanced Research Projects Agency for Health: The Mission

The Advanced Research Projects Agency for Health

Some breakthrough ideas don’t get enough attention because they’re too high-risk, high-cost, or long-term, because they don’t fit well into academia or the commercial sector, or because they require complex collaborations. ARPA-H aims to support promising opportunities which concern health but which fall in that gap. ARPA-H will have only extramural labs, and it will facilitate research directed at solving practical problems. ARPA-H is designed to be the DARPA of human health.

Get background information about ARPA-H.

Founding Director Dr. Renee Wegrzyn

Dr. Renee Wegrzyn is the inaugural director of ARPA-H. She brings to her post a distinguished record of service to the public and of achievement in the private sector.

Prior to Dr. Wegrzyn’s appointment by President Biden, she worked in the private sector as the Vice President of Business Development at Ginko Bioworks. There she worked on applications of synthetic biology to outpacing infectious diseases.

Earlier, she served as Program Manager with a $250 million portfolio in the Biological Technologies Office of the Defense Advanced Research Projects Agency (DARPA)—the organizational paradigm for the Advanced Research Projects Agency for Health. She also served as a technical advisor to the Intelligence Advanced Research Projects Activity (IARPA). At DARPA, Wegrzyn leveraged the tools of synthetic biology and gene editing to enhance biosecurity, support the domestic bioeconomy, and thwart biothreats. Wegrzyn received the Superior Public Service Medal for her work and contributions at DARPA.

Dr. Wegrzyn has also served as a Senior Advisor to the Nuclear Threat Initiative and as a member of the scientific advisory board for the National Academies Standing Committee on Biotechnology Capabilities and National Security Needs, and worked as the Senior Lead Technologist at Booz Allen Hamilton and the Leader of the Assay Development Group at Adlyfe, where her work included biosecurity and gene therapy.

She earned her BSc and PhD in Applied Biology from Georgia Tech, conducted post-doctoral research at the Center for Molecular Biology of Heidelberg University, and served as a fellow at the Center for Health Security Emerging Leaders in Biosecurity in the Bloomberg Schoolf of Public Health at the Johns Hopkins University.

Reserve Your Place Today

Register Now Free of Charge
For the 19th Annual Non-Dilutive Funding Summit (NDFS)
Wednesday, January 10, 2024
To Join Hundreds of Life Science Industry Leaders
In Learning about Non-Dilutive Funding Opportunities for Your R&D.

Speakers, location, and all other details to be announced.
Register now to receive updates.

Follow us on LinkedIn or request our newsletter to receive:

  • News about non-dilutive funding opportunities
  • Announcements about conferences with the best partnering for life science professionals
  • Discounts for those conferences.